Key Insights

Highlights

Success Rate

69% trial completion

Published Results

12 trials with published results (15%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

14.1%

11 terminated out of 78 trials

Success Rate

68.6%

-17.9% vs benchmark

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

50%

12 of 24 completed with results

Key Signals

12 with results69% success11 terminated

Data Visualizations

Phase Distribution

73Total
Not Applicable (2)
Early P 1 (6)
P 1 (47)
P 2 (15)
P 3 (3)

Trial Status

Completed24
Recruiting21
Terminated11
Active Not Recruiting10
Unknown6
Not Yet Recruiting2

Trial Success Rate

68.6%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (78)

Showing 20 of 20 trials
NCT04837547Phase 1Active Not Recruiting

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

NCT04099797Phase 1RecruitingPrimary

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

NCT01445288CompletedPrimary

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

NCT05843253Phase 2Recruiting

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

NCT06465199Phase 1Recruiting

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

NCT04185038Phase 1Recruiting

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

NCT07206849Phase 2Not Yet Recruiting

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

NCT05096481Phase 2Recruiting

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05839379Recruiting

Targeted Pediatric High-Grade Glioma Therapy

NCT03605550Phase 1Active Not Recruiting

A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

NCT04655404Early Phase 1Recruiting

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

NCT04943848Phase 1RecruitingPrimary

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT01165333Phase 1CompletedPrimary

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma

NCT06333899Early Phase 1Recruiting

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

NCT03033992Not ApplicableActive Not Recruiting

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT04978727Phase 1Active Not Recruiting

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT05476939Phase 3RecruitingPrimary

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

NCT05762419Phase 1RecruitingPrimary

FUS Etoposide for DMG

NCT04049669Phase 2Active Not Recruiting

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

NCT05009992Phase 2RecruitingPrimary

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Scroll to load more

Research Network

Activity Timeline